Monday, October 5, 2026

Explore How We Source Search

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Regulatory filingEU Digital Strategy

Commission Opinion on the assessment of the Code of Practice on Transparency of AI-generated content

View original at digital-strategy.ec.europa.eu

EU Digital Strategy - Ai Regulation Title: Commission Opinion on the assessment of the Code of Practice on Transparency of AI-generated content Date: 2026-07-09 07:03 Source: https://digital-strategy.ec.europa.eu/en/library/commission-opinion-assessment-code-practice-transparency-ai-generated-content <span>Commission O…

Opening lines of the source · EU Digital Strategy · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Adherence to the Code of Practice does not constitute conclusive evidence of compliance with the AI Act transparency obligations.
60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic

Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,985

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,985 facts checked against source5,340 source documents archived

Query this data → isubstrate.com